nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—Parkinson's disease—Bromocriptine—type 2 diabetes mellitus	0.314	1	CpDpCtD
Pramipexole—ADRA2A—type 2 diabetes mellitus	0.107	0.521	CbGaD
Pramipexole—HTR2C—type 2 diabetes mellitus	0.0989	0.479	CbGaD
Pramipexole—DRD5—Bromocriptine—type 2 diabetes mellitus	0.0386	0.132	CbGbCtD
Pramipexole—DRD4—Bromocriptine—type 2 diabetes mellitus	0.0275	0.0943	CbGbCtD
Pramipexole—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.0226	0.0776	CbGbCtD
Pramipexole—HTR2B—Bromocriptine—type 2 diabetes mellitus	0.0222	0.076	CbGbCtD
Pramipexole—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.0217	0.0744	CbGbCtD
Pramipexole—DRD3—Bromocriptine—type 2 diabetes mellitus	0.0205	0.0701	CbGbCtD
Pramipexole—DRD1—Bromocriptine—type 2 diabetes mellitus	0.0197	0.0676	CbGbCtD
Pramipexole—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.0197	0.0676	CbGbCtD
Pramipexole—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0187	0.0641	CbGbCtD
Pramipexole—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0144	0.0494	CbGbCtD
Pramipexole—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0136	0.0466	CbGbCtD
Pramipexole—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.013	0.0446	CbGbCtD
Pramipexole—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.013	0.0446	CbGbCtD
Pramipexole—DRD2—Bromocriptine—type 2 diabetes mellitus	0.012	0.0411	CbGbCtD
Pramipexole—SLC22A2—Metformin—type 2 diabetes mellitus	0.00778	0.0267	CbGbCtD
Pramipexole—SLC22A1—Metformin—type 2 diabetes mellitus	0.00676	0.0232	CbGbCtD
Pramipexole—HTR2A—arteriole—type 2 diabetes mellitus	0.00158	0.104	CbGeAlD
Pramipexole—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00101	0.0661	CbGeAlD
Pramipexole—DRD1—nerve—type 2 diabetes mellitus	0.000978	0.0641	CbGeAlD
Pramipexole—HTR1B—artery—type 2 diabetes mellitus	0.000799	0.0524	CbGeAlD
Pramipexole—HTR1D—artery—type 2 diabetes mellitus	0.000774	0.0507	CbGeAlD
Pramipexole—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000678	0.0444	CbGeAlD
Pramipexole—HTR2A—hindlimb—type 2 diabetes mellitus	0.000627	0.0411	CbGeAlD
Pramipexole—DRD2—nerve—type 2 diabetes mellitus	0.000578	0.0379	CbGeAlD
Pramipexole—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000575	0.0377	CbGeAlD
Pramipexole—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000489	0.0321	CbGeAlD
Pramipexole—SLC22A2—nephron tubule—type 2 diabetes mellitus	0.000428	0.028	CbGeAlD
Pramipexole—HTR2A—artery—type 2 diabetes mellitus	0.000384	0.0252	CbGeAlD
Pramipexole—HTR2A—nerve—type 2 diabetes mellitus	0.000381	0.025	CbGeAlD
Pramipexole—SLC22A2—kidney—type 2 diabetes mellitus	0.000376	0.0246	CbGeAlD
Pramipexole—SLC22A2—cortex of kidney—type 2 diabetes mellitus	0.000366	0.024	CbGeAlD
Pramipexole—HTR2A—endothelium—type 2 diabetes mellitus	0.000325	0.0213	CbGeAlD
Pramipexole—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000278	0.0182	CbGeAlD
Pramipexole—HTR1D—cardiovascular system—type 2 diabetes mellitus	0.000269	0.0176	CbGeAlD
Pramipexole—SLC22A1—kidney—type 2 diabetes mellitus	0.000265	0.0174	CbGeAlD
Pramipexole—HTR1D—kidney—type 2 diabetes mellitus	0.000263	0.0172	CbGeAlD
Pramipexole—HTR2B—cardiovascular system—type 2 diabetes mellitus	0.00025	0.0164	CbGeAlD
Pramipexole—DRD2—retina—type 2 diabetes mellitus	0.000239	0.0157	CbGeAlD
Pramipexole—SLC22A1—adipose tissue—type 2 diabetes mellitus	0.000239	0.0157	CbGeAlD
Pramipexole—HTR2B—cortex of kidney—type 2 diabetes mellitus	0.000238	0.0156	CbGeAlD
Pramipexole—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000224	0.0147	CbGeAlD
Pramipexole—HTR2B—adipose tissue—type 2 diabetes mellitus	0.000221	0.0145	CbGeAlD
Pramipexole—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000219	0.0144	CbGeAlD
Pramipexole—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000217	0.0142	CbGeAlD
Pramipexole—ADRA2C—kidney—type 2 diabetes mellitus	0.000193	0.0126	CbGeAlD
Pramipexole—ADRA2C—pancreas—type 2 diabetes mellitus	0.000191	0.0125	CbGeAlD
Pramipexole—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000188	0.0123	CbGeAlD
Pramipexole—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000174	0.0114	CbGeAlD
Pramipexole—SLC22A1—liver—type 2 diabetes mellitus	0.000168	0.011	CbGeAlD
Pramipexole—HTR2A—retina—type 2 diabetes mellitus	0.000158	0.0104	CbGeAlD
Pramipexole—ADRA2A—pancreas—type 2 diabetes mellitus	0.000153	0.01	CbGeAlD
Pramipexole—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.00015	0.00981	CbGeAlD
Pramipexole—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000139	0.00908	CbGeAlD
Pramipexole—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000134	0.00876	CbGeAlD
Pramipexole—HTR2A—kidney—type 2 diabetes mellitus	0.000131	0.00857	CbGeAlD
Pramipexole—ADRA2C—liver—type 2 diabetes mellitus	0.000122	0.00798	CbGeAlD
Pramipexole—HTR2A—liver—type 2 diabetes mellitus	8.26e-05	0.00542	CbGeAlD
Pramipexole—Malaise—Losartan—type 2 diabetes mellitus	2.57e-05	0.000225	CcSEcCtD
Pramipexole—Anxiety—Irbesartan—type 2 diabetes mellitus	2.57e-05	0.000225	CcSEcCtD
Pramipexole—Hypersensitivity—Glyburide—type 2 diabetes mellitus	2.57e-05	0.000225	CcSEcCtD
Pramipexole—Nervous system disorder—Metformin—type 2 diabetes mellitus	2.57e-05	0.000225	CcSEcCtD
Pramipexole—Thrombocytopenia—Metformin—type 2 diabetes mellitus	2.56e-05	0.000224	CcSEcCtD
Pramipexole—Dyspnoea—Valsartan—type 2 diabetes mellitus	2.56e-05	0.000224	CcSEcCtD
Pramipexole—Vertigo—Losartan—type 2 diabetes mellitus	2.56e-05	0.000224	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	2.56e-05	0.000224	CcSEcCtD
Pramipexole—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	2.56e-05	0.000224	CcSEcCtD
Pramipexole—Somnolence—Valsartan—type 2 diabetes mellitus	2.56e-05	0.000224	CcSEcCtD
Pramipexole—Syncope—Losartan—type 2 diabetes mellitus	2.55e-05	0.000223	CcSEcCtD
Pramipexole—Paraesthesia—Orlistat—type 2 diabetes mellitus	2.55e-05	0.000223	CcSEcCtD
Pramipexole—Leukopenia—Losartan—type 2 diabetes mellitus	2.55e-05	0.000223	CcSEcCtD
Pramipexole—Discomfort—Irbesartan—type 2 diabetes mellitus	2.55e-05	0.000223	CcSEcCtD
Pramipexole—Skin disorder—Metformin—type 2 diabetes mellitus	2.54e-05	0.000222	CcSEcCtD
Pramipexole—Immune system disorder—Ramipril—type 2 diabetes mellitus	2.53e-05	0.000222	CcSEcCtD
Pramipexole—Hyperhidrosis—Metformin—type 2 diabetes mellitus	2.53e-05	0.000221	CcSEcCtD
Pramipexole—Dyspepsia—Valsartan—type 2 diabetes mellitus	2.53e-05	0.000221	CcSEcCtD
Pramipexole—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	2.53e-05	0.000221	CcSEcCtD
Pramipexole—Dizziness—Bromocriptine—type 2 diabetes mellitus	2.52e-05	0.000221	CcSEcCtD
Pramipexole—Dry mouth—Irbesartan—type 2 diabetes mellitus	2.52e-05	0.00022	CcSEcCtD
Pramipexole—Palpitations—Losartan—type 2 diabetes mellitus	2.52e-05	0.00022	CcSEcCtD
Pramipexole—Nausea—Glimepiride—type 2 diabetes mellitus	2.51e-05	0.00022	CcSEcCtD
Pramipexole—Loss of consciousness—Losartan—type 2 diabetes mellitus	2.5e-05	0.000219	CcSEcCtD
Pramipexole—Nausea—Sitagliptin—type 2 diabetes mellitus	2.5e-05	0.000219	CcSEcCtD
Pramipexole—Dyspepsia—Orlistat—type 2 diabetes mellitus	2.5e-05	0.000219	CcSEcCtD
Pramipexole—Asthenia—Glyburide—type 2 diabetes mellitus	2.5e-05	0.000219	CcSEcCtD
Pramipexole—Decreased appetite—Valsartan—type 2 diabetes mellitus	2.5e-05	0.000219	CcSEcCtD
Pramipexole—Anorexia—Metformin—type 2 diabetes mellitus	2.5e-05	0.000218	CcSEcCtD
Pramipexole—Cough—Losartan—type 2 diabetes mellitus	2.49e-05	0.000217	CcSEcCtD
Pramipexole—Urticaria—Gliclazide—type 2 diabetes mellitus	2.49e-05	0.000217	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	2.48e-05	0.000217	CcSEcCtD
Pramipexole—Alopecia—Ramipril—type 2 diabetes mellitus	2.48e-05	0.000217	CcSEcCtD
Pramipexole—Fatigue—Valsartan—type 2 diabetes mellitus	2.48e-05	0.000217	CcSEcCtD
Pramipexole—Body temperature increased—Gliclazide—type 2 diabetes mellitus	2.47e-05	0.000216	CcSEcCtD
Pramipexole—Abdominal pain—Gliclazide—type 2 diabetes mellitus	2.47e-05	0.000216	CcSEcCtD
Pramipexole—Oedema—Irbesartan—type 2 diabetes mellitus	2.47e-05	0.000216	CcSEcCtD
Pramipexole—Decreased appetite—Orlistat—type 2 diabetes mellitus	2.47e-05	0.000216	CcSEcCtD
Pramipexole—Pruritus—Glyburide—type 2 diabetes mellitus	2.47e-05	0.000216	CcSEcCtD
Pramipexole—Mental disorder—Ramipril—type 2 diabetes mellitus	2.46e-05	0.000215	CcSEcCtD
Pramipexole—Constipation—Valsartan—type 2 diabetes mellitus	2.46e-05	0.000215	CcSEcCtD
Pramipexole—Infection—Irbesartan—type 2 diabetes mellitus	2.45e-05	0.000215	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	2.45e-05	0.000215	CcSEcCtD
Pramipexole—Fatigue—Orlistat—type 2 diabetes mellitus	2.45e-05	0.000214	CcSEcCtD
Pramipexole—Hypotension—Metformin—type 2 diabetes mellitus	2.45e-05	0.000214	CcSEcCtD
Pramipexole—Erythema—Ramipril—type 2 diabetes mellitus	2.44e-05	0.000214	CcSEcCtD
Pramipexole—Malnutrition—Ramipril—type 2 diabetes mellitus	2.44e-05	0.000214	CcSEcCtD
Pramipexole—Shock—Irbesartan—type 2 diabetes mellitus	2.43e-05	0.000213	CcSEcCtD
Pramipexole—Pain—Orlistat—type 2 diabetes mellitus	2.43e-05	0.000212	CcSEcCtD
Pramipexole—Chest pain—Losartan—type 2 diabetes mellitus	2.43e-05	0.000212	CcSEcCtD
Pramipexole—Myalgia—Losartan—type 2 diabetes mellitus	2.43e-05	0.000212	CcSEcCtD
Pramipexole—Arthralgia—Losartan—type 2 diabetes mellitus	2.43e-05	0.000212	CcSEcCtD
Pramipexole—Vomiting—Bromocriptine—type 2 diabetes mellitus	2.42e-05	0.000212	CcSEcCtD
Pramipexole—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	2.42e-05	0.000212	CcSEcCtD
Pramipexole—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	2.42e-05	0.000212	CcSEcCtD
Pramipexole—Anxiety—Losartan—type 2 diabetes mellitus	2.42e-05	0.000211	CcSEcCtD
Pramipexole—Tachycardia—Irbesartan—type 2 diabetes mellitus	2.41e-05	0.000211	CcSEcCtD
Pramipexole—Rash—Bromocriptine—type 2 diabetes mellitus	2.4e-05	0.00021	CcSEcCtD
Pramipexole—Dermatitis—Bromocriptine—type 2 diabetes mellitus	2.4e-05	0.00021	CcSEcCtD
Pramipexole—Skin disorder—Irbesartan—type 2 diabetes mellitus	2.4e-05	0.00021	CcSEcCtD
Pramipexole—Tension—Ramipril—type 2 diabetes mellitus	2.4e-05	0.00021	CcSEcCtD
Pramipexole—Discomfort—Losartan—type 2 diabetes mellitus	2.4e-05	0.00021	CcSEcCtD
Pramipexole—Dysgeusia—Ramipril—type 2 diabetes mellitus	2.39e-05	0.000209	CcSEcCtD
Pramipexole—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	2.39e-05	0.000209	CcSEcCtD
Pramipexole—Headache—Bromocriptine—type 2 diabetes mellitus	2.39e-05	0.000209	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	2.39e-05	0.000209	CcSEcCtD
Pramipexole—Diarrhoea—Glyburide—type 2 diabetes mellitus	2.38e-05	0.000209	CcSEcCtD
Pramipexole—Nervousness—Ramipril—type 2 diabetes mellitus	2.37e-05	0.000208	CcSEcCtD
Pramipexole—Dry mouth—Losartan—type 2 diabetes mellitus	2.37e-05	0.000207	CcSEcCtD
Pramipexole—Anorexia—Irbesartan—type 2 diabetes mellitus	2.36e-05	0.000206	CcSEcCtD
Pramipexole—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	2.35e-05	0.000206	CcSEcCtD
Pramipexole—Paraesthesia—Metformin—type 2 diabetes mellitus	2.35e-05	0.000206	CcSEcCtD
Pramipexole—Muscle spasms—Ramipril—type 2 diabetes mellitus	2.35e-05	0.000205	CcSEcCtD
Pramipexole—Confusional state—Losartan—type 2 diabetes mellitus	2.34e-05	0.000205	CcSEcCtD
Pramipexole—Feeling abnormal—Orlistat—type 2 diabetes mellitus	2.34e-05	0.000205	CcSEcCtD
Pramipexole—Dyspnoea—Metformin—type 2 diabetes mellitus	2.33e-05	0.000204	CcSEcCtD
Pramipexole—Somnolence—Metformin—type 2 diabetes mellitus	2.33e-05	0.000204	CcSEcCtD
Pramipexole—Oedema—Losartan—type 2 diabetes mellitus	2.33e-05	0.000203	CcSEcCtD
Pramipexole—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	2.32e-05	0.000203	CcSEcCtD
Pramipexole—Infection—Losartan—type 2 diabetes mellitus	2.31e-05	0.000202	CcSEcCtD
Pramipexole—Hypotension—Irbesartan—type 2 diabetes mellitus	2.31e-05	0.000202	CcSEcCtD
Pramipexole—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	2.31e-05	0.000202	CcSEcCtD
Pramipexole—Dyspepsia—Metformin—type 2 diabetes mellitus	2.3e-05	0.000202	CcSEcCtD
Pramipexole—Tremor—Ramipril—type 2 diabetes mellitus	2.29e-05	0.0002	CcSEcCtD
Pramipexole—Shock—Losartan—type 2 diabetes mellitus	2.29e-05	0.0002	CcSEcCtD
Pramipexole—Urticaria—Valsartan—type 2 diabetes mellitus	2.28e-05	0.0002	CcSEcCtD
Pramipexole—Nervous system disorder—Losartan—type 2 diabetes mellitus	2.28e-05	0.000199	CcSEcCtD
Pramipexole—Thrombocytopenia—Losartan—type 2 diabetes mellitus	2.28e-05	0.000199	CcSEcCtD
Pramipexole—Decreased appetite—Metformin—type 2 diabetes mellitus	2.28e-05	0.000199	CcSEcCtD
Pramipexole—Abdominal pain—Valsartan—type 2 diabetes mellitus	2.27e-05	0.000199	CcSEcCtD
Pramipexole—Tachycardia—Losartan—type 2 diabetes mellitus	2.27e-05	0.000199	CcSEcCtD
Pramipexole—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	2.27e-05	0.000198	CcSEcCtD
Pramipexole—Nausea—Bromocriptine—type 2 diabetes mellitus	2.26e-05	0.000198	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	2.26e-05	0.000198	CcSEcCtD
Pramipexole—Fatigue—Metformin—type 2 diabetes mellitus	2.26e-05	0.000197	CcSEcCtD
Pramipexole—Urticaria—Orlistat—type 2 diabetes mellitus	2.26e-05	0.000197	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	2.25e-05	0.000197	CcSEcCtD
Pramipexole—Hyperhidrosis—Losartan—type 2 diabetes mellitus	2.25e-05	0.000197	CcSEcCtD
Pramipexole—Abdominal pain—Orlistat—type 2 diabetes mellitus	2.25e-05	0.000196	CcSEcCtD
Pramipexole—Body temperature increased—Orlistat—type 2 diabetes mellitus	2.25e-05	0.000196	CcSEcCtD
Pramipexole—Asthenia—Gliclazide—type 2 diabetes mellitus	2.25e-05	0.000196	CcSEcCtD
Pramipexole—Agitation—Ramipril—type 2 diabetes mellitus	2.24e-05	0.000196	CcSEcCtD
Pramipexole—Constipation—Metformin—type 2 diabetes mellitus	2.24e-05	0.000196	CcSEcCtD
Pramipexole—Paraesthesia—Irbesartan—type 2 diabetes mellitus	2.22e-05	0.000194	CcSEcCtD
Pramipexole—Anorexia—Losartan—type 2 diabetes mellitus	2.22e-05	0.000194	CcSEcCtD
Pramipexole—Vomiting—Glyburide—type 2 diabetes mellitus	2.22e-05	0.000194	CcSEcCtD
Pramipexole—Pruritus—Gliclazide—type 2 diabetes mellitus	2.21e-05	0.000194	CcSEcCtD
Pramipexole—Malaise—Ramipril—type 2 diabetes mellitus	2.2e-05	0.000193	CcSEcCtD
Pramipexole—Dyspnoea—Irbesartan—type 2 diabetes mellitus	2.2e-05	0.000193	CcSEcCtD
Pramipexole—Rash—Glyburide—type 2 diabetes mellitus	2.2e-05	0.000192	CcSEcCtD
Pramipexole—Somnolence—Irbesartan—type 2 diabetes mellitus	2.2e-05	0.000192	CcSEcCtD
Pramipexole—Dermatitis—Glyburide—type 2 diabetes mellitus	2.2e-05	0.000192	CcSEcCtD
Pramipexole—Vertigo—Ramipril—type 2 diabetes mellitus	2.19e-05	0.000192	CcSEcCtD
Pramipexole—Syncope—Ramipril—type 2 diabetes mellitus	2.19e-05	0.000192	CcSEcCtD
Pramipexole—Leukopenia—Ramipril—type 2 diabetes mellitus	2.19e-05	0.000191	CcSEcCtD
Pramipexole—Headache—Glyburide—type 2 diabetes mellitus	2.18e-05	0.000191	CcSEcCtD
Pramipexole—Dyspepsia—Irbesartan—type 2 diabetes mellitus	2.17e-05	0.00019	CcSEcCtD
Pramipexole—Hypotension—Losartan—type 2 diabetes mellitus	2.17e-05	0.00019	CcSEcCtD
Pramipexole—Palpitations—Ramipril—type 2 diabetes mellitus	2.16e-05	0.000189	CcSEcCtD
Pramipexole—Feeling abnormal—Metformin—type 2 diabetes mellitus	2.16e-05	0.000189	CcSEcCtD
Pramipexole—Decreased appetite—Irbesartan—type 2 diabetes mellitus	2.15e-05	0.000188	CcSEcCtD
Pramipexole—Loss of consciousness—Ramipril—type 2 diabetes mellitus	2.15e-05	0.000188	CcSEcCtD
Pramipexole—Diarrhoea—Gliclazide—type 2 diabetes mellitus	2.14e-05	0.000187	CcSEcCtD
Pramipexole—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	2.14e-05	0.000187	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	2.13e-05	0.000187	CcSEcCtD
Pramipexole—Cough—Ramipril—type 2 diabetes mellitus	2.13e-05	0.000186	CcSEcCtD
Pramipexole—Fatigue—Irbesartan—type 2 diabetes mellitus	2.13e-05	0.000186	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	2.12e-05	0.000185	CcSEcCtD
Pramipexole—Hypersensitivity—Valsartan—type 2 diabetes mellitus	2.12e-05	0.000185	CcSEcCtD
Pramipexole—Convulsion—Ramipril—type 2 diabetes mellitus	2.12e-05	0.000185	CcSEcCtD
Pramipexole—Pain—Irbesartan—type 2 diabetes mellitus	2.11e-05	0.000185	CcSEcCtD
Pramipexole—Constipation—Irbesartan—type 2 diabetes mellitus	2.11e-05	0.000185	CcSEcCtD
Pramipexole—Insomnia—Losartan—type 2 diabetes mellitus	2.1e-05	0.000184	CcSEcCtD
Pramipexole—Hypersensitivity—Orlistat—type 2 diabetes mellitus	2.09e-05	0.000183	CcSEcCtD
Pramipexole—Paraesthesia—Losartan—type 2 diabetes mellitus	2.09e-05	0.000183	CcSEcCtD
Pramipexole—Urticaria—Metformin—type 2 diabetes mellitus	2.08e-05	0.000182	CcSEcCtD
Pramipexole—Arthralgia—Ramipril—type 2 diabetes mellitus	2.08e-05	0.000182	CcSEcCtD
Pramipexole—Chest pain—Ramipril—type 2 diabetes mellitus	2.08e-05	0.000182	CcSEcCtD
Pramipexole—Myalgia—Ramipril—type 2 diabetes mellitus	2.08e-05	0.000182	CcSEcCtD
Pramipexole—Dyspnoea—Losartan—type 2 diabetes mellitus	2.07e-05	0.000181	CcSEcCtD
Pramipexole—Anxiety—Ramipril—type 2 diabetes mellitus	2.07e-05	0.000181	CcSEcCtD
Pramipexole—Nausea—Glyburide—type 2 diabetes mellitus	2.07e-05	0.000181	CcSEcCtD
Pramipexole—Abdominal pain—Metformin—type 2 diabetes mellitus	2.07e-05	0.000181	CcSEcCtD
Pramipexole—Dizziness—Gliclazide—type 2 diabetes mellitus	2.07e-05	0.000181	CcSEcCtD
Pramipexole—Somnolence—Losartan—type 2 diabetes mellitus	2.07e-05	0.000181	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	2.07e-05	0.000181	CcSEcCtD
Pramipexole—Asthenia—Valsartan—type 2 diabetes mellitus	2.06e-05	0.00018	CcSEcCtD
Pramipexole—Discomfort—Ramipril—type 2 diabetes mellitus	2.05e-05	0.00018	CcSEcCtD
Pramipexole—Dyspepsia—Losartan—type 2 diabetes mellitus	2.05e-05	0.000179	CcSEcCtD
Pramipexole—Asthenia—Orlistat—type 2 diabetes mellitus	2.04e-05	0.000178	CcSEcCtD
Pramipexole—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	2.04e-05	0.000178	CcSEcCtD
Pramipexole—Pruritus—Valsartan—type 2 diabetes mellitus	2.03e-05	0.000178	CcSEcCtD
Pramipexole—Dry mouth—Ramipril—type 2 diabetes mellitus	2.03e-05	0.000178	CcSEcCtD
Pramipexole—Decreased appetite—Losartan—type 2 diabetes mellitus	2.02e-05	0.000177	CcSEcCtD
Pramipexole—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	2.02e-05	0.000177	CcSEcCtD
Pramipexole—Confusional state—Ramipril—type 2 diabetes mellitus	2.01e-05	0.000176	CcSEcCtD
Pramipexole—Pruritus—Orlistat—type 2 diabetes mellitus	2.01e-05	0.000176	CcSEcCtD
Pramipexole—Fatigue—Losartan—type 2 diabetes mellitus	2e-05	0.000175	CcSEcCtD
Pramipexole—Oedema—Ramipril—type 2 diabetes mellitus	1.99e-05	0.000174	CcSEcCtD
Pramipexole—Vomiting—Gliclazide—type 2 diabetes mellitus	1.99e-05	0.000174	CcSEcCtD
Pramipexole—Constipation—Losartan—type 2 diabetes mellitus	1.99e-05	0.000174	CcSEcCtD
Pramipexole—Pain—Losartan—type 2 diabetes mellitus	1.99e-05	0.000174	CcSEcCtD
Pramipexole—Rash—Gliclazide—type 2 diabetes mellitus	1.97e-05	0.000173	CcSEcCtD
Pramipexole—Dermatitis—Gliclazide—type 2 diabetes mellitus	1.97e-05	0.000172	CcSEcCtD
Pramipexole—Diarrhoea—Valsartan—type 2 diabetes mellitus	1.97e-05	0.000172	CcSEcCtD
Pramipexole—Urticaria—Irbesartan—type 2 diabetes mellitus	1.96e-05	0.000172	CcSEcCtD
Pramipexole—Shock—Ramipril—type 2 diabetes mellitus	1.96e-05	0.000172	CcSEcCtD
Pramipexole—Headache—Gliclazide—type 2 diabetes mellitus	1.96e-05	0.000171	CcSEcCtD
Pramipexole—Nervous system disorder—Ramipril—type 2 diabetes mellitus	1.96e-05	0.000171	CcSEcCtD
Pramipexole—Body temperature increased—Irbesartan—type 2 diabetes mellitus	1.95e-05	0.000171	CcSEcCtD
Pramipexole—Abdominal pain—Irbesartan—type 2 diabetes mellitus	1.95e-05	0.000171	CcSEcCtD
Pramipexole—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	1.95e-05	0.000171	CcSEcCtD
Pramipexole—Tachycardia—Ramipril—type 2 diabetes mellitus	1.95e-05	0.00017	CcSEcCtD
Pramipexole—Diarrhoea—Orlistat—type 2 diabetes mellitus	1.94e-05	0.00017	CcSEcCtD
Pramipexole—Skin disorder—Ramipril—type 2 diabetes mellitus	1.94e-05	0.000169	CcSEcCtD
Pramipexole—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	1.93e-05	0.000169	CcSEcCtD
Pramipexole—Feeling abnormal—Losartan—type 2 diabetes mellitus	1.92e-05	0.000168	CcSEcCtD
Pramipexole—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	1.9e-05	0.000166	CcSEcCtD
Pramipexole—Dizziness—Valsartan—type 2 diabetes mellitus	1.9e-05	0.000166	CcSEcCtD
Pramipexole—Anorexia—Ramipril—type 2 diabetes mellitus	1.9e-05	0.000166	CcSEcCtD
Pramipexole—Dizziness—Orlistat—type 2 diabetes mellitus	1.88e-05	0.000164	CcSEcCtD
Pramipexole—Asthenia—Metformin—type 2 diabetes mellitus	1.88e-05	0.000164	CcSEcCtD
Pramipexole—Hypotension—Ramipril—type 2 diabetes mellitus	1.86e-05	0.000163	CcSEcCtD
Pramipexole—Nausea—Gliclazide—type 2 diabetes mellitus	1.86e-05	0.000163	CcSEcCtD
Pramipexole—Pruritus—Metformin—type 2 diabetes mellitus	1.85e-05	0.000162	CcSEcCtD
Pramipexole—Urticaria—Losartan—type 2 diabetes mellitus	1.85e-05	0.000162	CcSEcCtD
Pramipexole—Abdominal pain—Losartan—type 2 diabetes mellitus	1.84e-05	0.000161	CcSEcCtD
Pramipexole—Body temperature increased—Losartan—type 2 diabetes mellitus	1.84e-05	0.000161	CcSEcCtD
Pramipexole—Vomiting—Valsartan—type 2 diabetes mellitus	1.83e-05	0.00016	CcSEcCtD
Pramipexole—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	1.82e-05	0.000159	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	1.82e-05	0.000159	CcSEcCtD
Pramipexole—Rash—Valsartan—type 2 diabetes mellitus	1.81e-05	0.000159	CcSEcCtD
Pramipexole—Dermatitis—Valsartan—type 2 diabetes mellitus	1.81e-05	0.000158	CcSEcCtD
Pramipexole—Vomiting—Orlistat—type 2 diabetes mellitus	1.81e-05	0.000158	CcSEcCtD
Pramipexole—Insomnia—Ramipril—type 2 diabetes mellitus	1.8e-05	0.000158	CcSEcCtD
Pramipexole—Headache—Valsartan—type 2 diabetes mellitus	1.8e-05	0.000158	CcSEcCtD
Pramipexole—Diarrhoea—Metformin—type 2 diabetes mellitus	1.79e-05	0.000157	CcSEcCtD
Pramipexole—Rash—Orlistat—type 2 diabetes mellitus	1.79e-05	0.000157	CcSEcCtD
Pramipexole—Paraesthesia—Ramipril—type 2 diabetes mellitus	1.79e-05	0.000157	CcSEcCtD
Pramipexole—Dermatitis—Orlistat—type 2 diabetes mellitus	1.79e-05	0.000157	CcSEcCtD
Pramipexole—Headache—Orlistat—type 2 diabetes mellitus	1.78e-05	0.000156	CcSEcCtD
Pramipexole—Dyspnoea—Ramipril—type 2 diabetes mellitus	1.78e-05	0.000155	CcSEcCtD
Pramipexole—Asthenia—Irbesartan—type 2 diabetes mellitus	1.77e-05	0.000155	CcSEcCtD
Pramipexole—Somnolence—Ramipril—type 2 diabetes mellitus	1.77e-05	0.000155	CcSEcCtD
Pramipexole—Dyspepsia—Ramipril—type 2 diabetes mellitus	1.75e-05	0.000154	CcSEcCtD
Pramipexole—Pruritus—Irbesartan—type 2 diabetes mellitus	1.75e-05	0.000153	CcSEcCtD
Pramipexole—Decreased appetite—Ramipril—type 2 diabetes mellitus	1.73e-05	0.000152	CcSEcCtD
Pramipexole—Dizziness—Metformin—type 2 diabetes mellitus	1.73e-05	0.000151	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	1.72e-05	0.000151	CcSEcCtD
Pramipexole—Fatigue—Ramipril—type 2 diabetes mellitus	1.72e-05	0.00015	CcSEcCtD
Pramipexole—Hypersensitivity—Losartan—type 2 diabetes mellitus	1.71e-05	0.00015	CcSEcCtD
Pramipexole—Nausea—Valsartan—type 2 diabetes mellitus	1.71e-05	0.000149	CcSEcCtD
Pramipexole—Constipation—Ramipril—type 2 diabetes mellitus	1.7e-05	0.000149	CcSEcCtD
Pramipexole—Diarrhoea—Irbesartan—type 2 diabetes mellitus	1.69e-05	0.000148	CcSEcCtD
Pramipexole—Nausea—Orlistat—type 2 diabetes mellitus	1.69e-05	0.000148	CcSEcCtD
Pramipexole—Asthenia—Losartan—type 2 diabetes mellitus	1.67e-05	0.000146	CcSEcCtD
Pramipexole—Vomiting—Metformin—type 2 diabetes mellitus	1.66e-05	0.000146	CcSEcCtD
Pramipexole—Rash—Metformin—type 2 diabetes mellitus	1.65e-05	0.000144	CcSEcCtD
Pramipexole—Dermatitis—Metformin—type 2 diabetes mellitus	1.65e-05	0.000144	CcSEcCtD
Pramipexole—Pruritus—Losartan—type 2 diabetes mellitus	1.65e-05	0.000144	CcSEcCtD
Pramipexole—Feeling abnormal—Ramipril—type 2 diabetes mellitus	1.64e-05	0.000144	CcSEcCtD
Pramipexole—Headache—Metformin—type 2 diabetes mellitus	1.64e-05	0.000143	CcSEcCtD
Pramipexole—Dizziness—Irbesartan—type 2 diabetes mellitus	1.63e-05	0.000143	CcSEcCtD
Pramipexole—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	1.63e-05	0.000143	CcSEcCtD
Pramipexole—Diarrhoea—Losartan—type 2 diabetes mellitus	1.59e-05	0.000139	CcSEcCtD
Pramipexole—Urticaria—Ramipril—type 2 diabetes mellitus	1.58e-05	0.000139	CcSEcCtD
Pramipexole—Abdominal pain—Ramipril—type 2 diabetes mellitus	1.58e-05	0.000138	CcSEcCtD
Pramipexole—Body temperature increased—Ramipril—type 2 diabetes mellitus	1.58e-05	0.000138	CcSEcCtD
Pramipexole—Vomiting—Irbesartan—type 2 diabetes mellitus	1.57e-05	0.000137	CcSEcCtD
Pramipexole—Rash—Irbesartan—type 2 diabetes mellitus	1.56e-05	0.000136	CcSEcCtD
Pramipexole—Dermatitis—Irbesartan—type 2 diabetes mellitus	1.56e-05	0.000136	CcSEcCtD
Pramipexole—Nausea—Metformin—type 2 diabetes mellitus	1.56e-05	0.000136	CcSEcCtD
Pramipexole—Headache—Irbesartan—type 2 diabetes mellitus	1.55e-05	0.000135	CcSEcCtD
Pramipexole—Dizziness—Losartan—type 2 diabetes mellitus	1.54e-05	0.000134	CcSEcCtD
Pramipexole—Vomiting—Losartan—type 2 diabetes mellitus	1.48e-05	0.000129	CcSEcCtD
Pramipexole—Hypersensitivity—Ramipril—type 2 diabetes mellitus	1.47e-05	0.000128	CcSEcCtD
Pramipexole—Nausea—Irbesartan—type 2 diabetes mellitus	1.47e-05	0.000128	CcSEcCtD
Pramipexole—Rash—Losartan—type 2 diabetes mellitus	1.47e-05	0.000128	CcSEcCtD
Pramipexole—Dermatitis—Losartan—type 2 diabetes mellitus	1.46e-05	0.000128	CcSEcCtD
Pramipexole—Headache—Losartan—type 2 diabetes mellitus	1.46e-05	0.000127	CcSEcCtD
Pramipexole—Asthenia—Ramipril—type 2 diabetes mellitus	1.43e-05	0.000125	CcSEcCtD
Pramipexole—Pruritus—Ramipril—type 2 diabetes mellitus	1.41e-05	0.000123	CcSEcCtD
Pramipexole—Nausea—Losartan—type 2 diabetes mellitus	1.38e-05	0.000121	CcSEcCtD
Pramipexole—Diarrhoea—Ramipril—type 2 diabetes mellitus	1.36e-05	0.000119	CcSEcCtD
Pramipexole—Dizziness—Ramipril—type 2 diabetes mellitus	1.32e-05	0.000115	CcSEcCtD
Pramipexole—Vomiting—Ramipril—type 2 diabetes mellitus	1.27e-05	0.000111	CcSEcCtD
Pramipexole—Rash—Ramipril—type 2 diabetes mellitus	1.26e-05	0.00011	CcSEcCtD
Pramipexole—Dermatitis—Ramipril—type 2 diabetes mellitus	1.26e-05	0.00011	CcSEcCtD
Pramipexole—Headache—Ramipril—type 2 diabetes mellitus	1.25e-05	0.000109	CcSEcCtD
Pramipexole—Nausea—Ramipril—type 2 diabetes mellitus	1.18e-05	0.000104	CcSEcCtD
Pramipexole—HTR1A—Signaling Pathways—INS—type 2 diabetes mellitus	1.69e-06	2.89e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.69e-06	2.89e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.69e-06	2.89e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.69e-06	2.88e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.68e-06	2.88e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—INS—type 2 diabetes mellitus	1.68e-06	2.88e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.68e-06	2.87e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	1.67e-06	2.86e-05	CbGpPWpGaD
Pramipexole—HTR1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.67e-06	2.85e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.67e-06	2.84e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.66e-06	2.83e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.65e-06	2.83e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.65e-06	2.81e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—NOS3—type 2 diabetes mellitus	1.65e-06	2.81e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.64e-06	2.81e-05	CbGpPWpGaD
Pramipexole—DRD4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.64e-06	2.81e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.64e-06	2.8e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	1.64e-06	2.8e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.64e-06	2.8e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.64e-06	2.79e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.63e-06	2.78e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.63e-06	2.78e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.63e-06	2.78e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.63e-06	2.78e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.62e-06	2.77e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	1.62e-06	2.77e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.62e-06	2.77e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.62e-06	2.76e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PTGS2—type 2 diabetes mellitus	1.62e-06	2.76e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.61e-06	2.76e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.61e-06	2.75e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.61e-06	2.75e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—RELA—type 2 diabetes mellitus	1.6e-06	2.74e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.6e-06	2.73e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.6e-06	2.72e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.59e-06	2.72e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	1.59e-06	2.72e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.59e-06	2.71e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.58e-06	2.71e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.58e-06	2.7e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	1.58e-06	2.7e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.58e-06	2.7e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.58e-06	2.69e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	1.57e-06	2.68e-05	CbGpPWpGaD
Pramipexole—HTR2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.57e-06	2.68e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.56e-06	2.67e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.56e-06	2.67e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.56e-06	2.66e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.56e-06	2.66e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.55e-06	2.66e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.55e-06	2.65e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.55e-06	2.65e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.55e-06	2.64e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.55e-06	2.64e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.55e-06	2.64e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.54e-06	2.64e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.54e-06	2.63e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.54e-06	2.63e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.54e-06	2.63e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.54e-06	2.63e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.53e-06	2.61e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.52e-06	2.6e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.52e-06	2.59e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PTGS2—type 2 diabetes mellitus	1.51e-06	2.57e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.5e-06	2.57e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.49e-06	2.55e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—INS—type 2 diabetes mellitus	1.49e-06	2.54e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.48e-06	2.53e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.48e-06	2.53e-05	CbGpPWpGaD
Pramipexole—DRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.48e-06	2.53e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.48e-06	2.52e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.48e-06	2.52e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—SRC—type 2 diabetes mellitus	1.47e-06	2.51e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.47e-06	2.51e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.47e-06	2.51e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.47e-06	2.5e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.46e-06	2.5e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.46e-06	2.5e-05	CbGpPWpGaD
Pramipexole—DRD3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.46e-06	2.49e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	1.46e-06	2.49e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.46e-06	2.49e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.45e-06	2.48e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.45e-06	2.47e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.45e-06	2.47e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.44e-06	2.46e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.44e-06	2.46e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.44e-06	2.45e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.44e-06	2.45e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.44e-06	2.45e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.44e-06	2.45e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.44e-06	2.45e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.43e-06	2.45e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.43e-06	2.44e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.42e-06	2.43e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—SRC—type 2 diabetes mellitus	1.42e-06	2.42e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.41e-06	2.42e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.41e-06	2.41e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.41e-06	2.4e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.4e-06	2.4e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.4e-06	2.39e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	1.4e-06	2.38e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	1.4e-06	2.38e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	1.39e-06	2.37e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.39e-06	2.37e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.39e-06	2.37e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.38e-06	2.36e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.37e-06	2.34e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.37e-06	2.33e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.37e-06	2.33e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.35e-06	2.31e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	1.35e-06	2.31e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.35e-06	2.31e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.34e-06	2.29e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.34e-06	2.29e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.33e-06	2.27e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.33e-06	2.26e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.32e-06	2.25e-05	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.32e-06	2.25e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.32e-06	2.25e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.31e-06	2.24e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.31e-06	2.23e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.3e-06	2.23e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.3e-06	2.23e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.3e-06	2.22e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.29e-06	2.21e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.29e-06	2.2e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.29e-06	2.2e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.29e-06	2.2e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.29e-06	2.2e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.28e-06	2.19e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.28e-06	2.19e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.28e-06	2.19e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.28e-06	2.18e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	1.28e-06	2.18e-05	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.27e-06	2.17e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.27e-06	2.17e-05	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.27e-06	2.16e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.26e-06	2.16e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.26e-06	2.15e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—SRC—type 2 diabetes mellitus	1.26e-06	2.15e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.25e-06	2.14e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.25e-06	2.14e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.25e-06	2.13e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.24e-06	2.12e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.24e-06	2.12e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.23e-06	2.11e-05	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.23e-06	2.1e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.23e-06	2.1e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.23e-06	2.1e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.22e-06	2.09e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.22e-06	2.08e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.22e-06	2.08e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.21e-06	2.07e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.21e-06	2.07e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.21e-06	2.06e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.2e-06	2.04e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.19e-06	2.04e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.19e-06	2.03e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.19e-06	2.03e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.18e-06	2.02e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.18e-06	2.01e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.17e-06	2e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.17e-06	1.99e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.17e-06	1.99e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.16e-06	1.97e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.15e-06	1.97e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.15e-06	1.96e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.14e-06	1.95e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.14e-06	1.95e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.14e-06	1.94e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.13e-06	1.92e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.12e-06	1.91e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.12e-06	1.91e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.12e-06	1.91e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.11e-06	1.89e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.11e-06	1.89e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.1e-06	1.89e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.1e-06	1.88e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.1e-06	1.88e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.1e-06	1.88e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.1e-06	1.88e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.09e-06	1.87e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.09e-06	1.86e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.08e-06	1.85e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.07e-06	1.83e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.06e-06	1.82e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.06e-06	1.81e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.05e-06	1.79e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.03e-06	1.77e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.03e-06	1.77e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.03e-06	1.76e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.02e-06	1.74e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.02e-06	1.74e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.01e-06	1.73e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1e-06	1.71e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.98e-07	1.7e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.97e-07	1.7e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	9.92e-07	1.69e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.91e-07	1.69e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.84e-07	1.68e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.82e-07	1.68e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.77e-07	1.67e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	9.71e-07	1.66e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	9.64e-07	1.65e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.62e-07	1.64e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.58e-07	1.64e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—type 2 diabetes mellitus	9.56e-07	1.63e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.5e-07	1.62e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	9.49e-07	1.62e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.39e-07	1.6e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.36e-07	1.6e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.31e-07	1.59e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.26e-07	1.58e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.24e-07	1.58e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.15e-07	1.56e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—type 2 diabetes mellitus	9.12e-07	1.56e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.08e-07	1.55e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.96e-07	1.53e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.82e-07	1.51e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	8.63e-07	1.47e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.62e-07	1.47e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	8.6e-07	1.47e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—type 2 diabetes mellitus	8.49e-07	1.45e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.48e-07	1.45e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.45e-07	1.44e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.41e-07	1.44e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.41e-07	1.44e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.31e-07	1.42e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—AKT1—type 2 diabetes mellitus	8.12e-07	1.39e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.94e-07	1.36e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	7.9e-07	1.35e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.83e-07	1.34e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.72e-07	1.32e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	7.66e-07	1.31e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—AKT1—type 2 diabetes mellitus	7.57e-07	1.29e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.56e-07	1.29e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	7.4e-07	1.26e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	7.36e-07	1.26e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	7.16e-07	1.22e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.07e-07	1.21e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.82e-07	1.17e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.79e-07	1.16e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.6e-07	1.13e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	6.49e-07	1.11e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	6.41e-07	1.1e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.39e-07	1.09e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.99e-07	1.02e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.9e-07	1.01e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	5.81e-07	9.93e-06	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.36e-07	9.16e-06	CbGpPWpGaD
